BUZZ-Hepion tumbles after discontinuing trial for fatty liver disease treatment

Reuters04-20

** Shares of drug developer Hepion Pharmaceuticals fall 33.8% to $1.30 in extended trading

** Company says it is winding down a mid-stage trial evaluating the drug rencofilstat for the treatment of a fatty liver disease known as non-alcoholic steatohepatitis

** There is low probability of generating relevant efficacy data given its current cash resources - Hepion

** Company is continuing to explore strategic alternatives

** Up to last close, stock down 86.4% in last 12 months

(Reporting by Christy Santhosh)

((Christy.Santhosh@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2428694783?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-04-20 05:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2428694783","market":"us","top_or_hot":-1,"title":"BUZZ-Hepion tumbles after discontinuing trial for fatty liver disease treatment","media":"Reuters","content":"<html><body><p>** Shares of drug developer Hepion Pharmaceuticals    fall 33.8% to $1.30 in extended trading</p><p>   ** Company says it is winding down a mid-stage trial evaluating the drug rencofilstat for the treatment of a fatty liver disease known as non-alcoholic steatohepatitis</p><p>   ** There is low probability of generating relevant efficacy data given its current cash resources - Hepion</p><p>   ** Company is continuing to explore strategic alternatives</p><p>   ** Up to last close, stock down 86.4% in last 12 months</p><p> (Reporting by Christy Santhosh)</p><p>((Christy.Santhosh@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Hepion tumbles after discontinuing trial for fatty liver disease treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Hepion tumbles after discontinuing trial for fatty liver disease treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-20 05:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>** Shares of drug developer Hepion Pharmaceuticals    fall 33.8% to $1.30 in extended trading   ** Company says it is winding down a mid-stage trial evaluating the drug rencofilstat for the treatment ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2428694783","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2428694783","pubTimestamp":1713562447,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"** Shares of drug developer Hepion Pharmaceuticals    fall 33.8% to $1.30 in extended trading   ** Company says it is winding down a mid-stage trial evaluating the drug rencofilstat for the treatment of a fatty liver disease known as non-alcoholic steatohepatitis   ** There is low probability of generating relevant efficacy data given its current cash resources - Hepion   ** Company is continuing to explore strategic alternatives   ** Up to last close, stock down 86.4% in last 12 months ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","HEPA":"Hepion Pharmaceuticals, Inc.","BUZZ":"VanEck Social Sentiment ETF"},"translate_title":"BUZZ-Hepion在停止脂肪肝治疗试验后出现问题","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BUZZ":1,"HEPA":0.9},"content_text":"** Shares of drug developer Hepion Pharmaceuticals    fall 33.8% to $1.30 in extended trading   ** Company says it is winding down a mid-stage trial evaluating the drug rencofilstat for the treatment of a fatty liver disease known as non-alcoholic steatohepatitis   ** There is low probability of generating relevant efficacy data given its current cash resources - Hepion   ** Company is continuing to explore strategic alternatives   ** Up to last close, stock down 86.4% in last 12 months (Reporting by Christy Santhosh)((Christy.Santhosh@thomsonreuters.com))","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.0","shortVersion":"4.24.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2428694783"}